Abstract Number: 1357 • 2016 ACR/ARHP Annual Meeting
Clinical Description of Patients with Cytoplasmic Discrete Speckles on Indirect Immunofluorescence on HEp-2 Cells in a Universitary Hospital
Background/Purpose: Indirect Immunofluorescence (IIF) shows different nuclear and cytoplasmic fluorescence patterns depending on the antibodies present in the cell. Cytoplasmic patterns are an unusual finding.…Abstract Number: 1358 • 2016 ACR/ARHP Annual Meeting
Response of Hidradenitis Suppurativa to Biologic Therapy
Response of Hidradenitis Suppurativa to Biologic Therapy Background/Purpose: Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory disease of apocrine sweat glands, characterized by recurrent abscessing…Abstract Number: 1359 • 2016 ACR/ARHP Annual Meeting
New Markers for Celiac Disease: Anti-Neo-Epitope Human and Microbial Transglutaminases
Background/Purpose: Microbial transglutaminase (mTg) and human tissue Tg (tTg) complexed to gliadin peptides present neo-epitopes. Antibodies against these complexes are called tTg neo-epitope and mTg…Abstract Number: 1360 • 2016 ACR/ARHP Annual Meeting
Discontinuation Causes of Biological Therapies: Over a Five-Year Period. Biobadasar
Background/Purpose: To analyze discontinuation causes of biologics therapies (bDMARDs) in patients who are registered in the database BIOBADASAR. Methods: Database included demographics of patients, type…Abstract Number: 1361 • 2016 ACR/ARHP Annual Meeting
The Role of Von Willebrand Factor Antigen As a Disease Biomarker in the Clinical Assessment of Children with Juvenile Dermatomyositis
Background/Purpose: With the advent of new therapies, outcomes for children with juvenile dermatomyositis (JDM) have significantly improved. Accurate markers of clinically inactivedisease are thus fundamental…Abstract Number: 1362 • 2016 ACR/ARHP Annual Meeting
Associations Between 25-Hydroxyvitamin D, Parathyroid Hormone, and Cathelicidin Concentrations with Inflammation and Cardiovascular Risk in Subjects with Pediatric Systemic Lupus Erythematosus
Background/Purpose: Previous studies have shown associations between reduced serum 25-hydroxyvitamin D (25OHD) levels, inflammation, and disease activity in pediatric systemic lupus erythematosus (pSLE). The goal…Abstract Number: 1363 • 2016 ACR/ARHP Annual Meeting
Serum Adipokines in Juvenile Dermatomyositis Are Associated with Disease Activities and Cardiac Function
Background/Purpose: We have earlier demonstrated redistribution of adipose tissue in JDM patients. There is an increase in visceral adipose tissue (VAT), a highly active metabolic…Abstract Number: 1364 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tumour Necrosis Factor Antagonists in a Large Cohort of Juvenile Dermatomyositis Patients
Background/Purpose: Some patients with juvenile dermatomyositis (JDM) have a disease course which is refractory to multiple drug treatments. There is evidence that prolonged disease activity…Abstract Number: 1365 • 2016 ACR/ARHP Annual Meeting
Trends in Medication Usage in Patients with Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with characteristic rashes and chronic muscle inflammation. Because of its rarity, most therapeutic choices are based…Abstract Number: 1366 • 2016 ACR/ARHP Annual Meeting
Evidence Based Criteria for Corticosteroid Tapering/Discontinuation. an Analysis of the Paediatric Rheumatology International Trials Organization (PRINTO) Trial in New Onset Juvenile Dermatomyositis
Background/Purpose: Corticosteroids in juvenile dermatomyositis (JDM) alone or in association with other immunosuppressive drugs, namely methotrexate (MTX) and cyclosporine (CSA), represent the first-line treatment option for…Abstract Number: 1367 • 2016 ACR/ARHP Annual Meeting
Long-Term Outcomes and Their Predictors in Patients with Juvenile Idiopathic Inflammatory Myopathies of Adult Age: A Referral Population Study
Background/Purpose: To investigate the long-term outcomes and prognostic factors for pts with juvenile-onset idiopathic inflammatory myopathies (JIIM) who are currently adults. Methods: Adults with JIIM…Abstract Number: 1368 • 2016 ACR/ARHP Annual Meeting
Clinical Course of Juvenile Dermatomyositis Presenting As Skin Predominant Disease
Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic inflammatory disorder of the skin and striated muscle. A subset of patients can present with rash only, labeled…Abstract Number: 1369 • 2016 ACR/ARHP Annual Meeting
Features Distinguishing Clinically Hypo- and Amyopathic Juvenile Dermatomyositis (CAJDM) from Juvenile Dermatomyositis (JDM)
Background/Purpose: Clinically Amyopathic Juvenile Dermatomyositis (CAJDM) is a distinct clinical phenotype of JDM in which patients (pts) often have characteristic JDM rashes with little…Abstract Number: 1370 • 2016 ACR/ARHP Annual Meeting
Development and Validation of a Composite Disease Activity Score for Juvenile Dermatomyositis
Background/Purpose: JDM is a multisystem vasculopathic disease that primarily affects the skin and muscles. Most tools for assessment of disease activity in JDM are lenghty,…Abstract Number: 1371 • 2016 ACR/ARHP Annual Meeting
Comparison of Patient and Physician Reported Global Disease Activity Measures in Juvenile Dermatomyositis
Background/Purpose: Patient reported outcomes (PROs) are becoming increasingly recognized as important in the care of patients with chronic diseases, such as Juvenile Dermatomyositis (JDM); however,…
ACR Meeting Abstracts